A landmark human trial tests whether cellular reprogramming can safely reverse aging, separating science from hype in the billion-dollar quest for extended lifespan.

The first human trial of cellular reprogramming—targeting glaucoma via partial cell rejuvenation—represents a watershed for longevity science. Unlike lifestyle interventions or unproven plas...

Cellular reprogramming leverages epigenetic mechanisms to reset aging cells to a younger state. The trial’s therapy, developed by Life Biosciences, targets three genes (Yamanaka factors) to ...

Tech billionaires are fueling the longevity gold rush, with investments totaling over $5 billion since 2022. Brian Armstrong (Coinbase) backs NewLimit ($3.1B valuation), Sam Altman (OpenAI) ...

The 2026 cellular reprogramming trial is a litmus test for longevity medicine’s credibility. Success could catalyze a paradigm shift in aging research, validating epigenetic rejuvenation as a therapeutic tool. Failure, however, risks relegating the field to the realm of speculative science, at least temporarily. The trial’s narrow focus on glaucoma—while pragmatic—highlights the tension between scientific caution and industry hype. With billions in funding and tech titans at the helm, the stakes extend beyond biology to economics, ethics, and global health policy.